| 32nd week of 2015 patent applcation highlights part 8 |
| Patent application number | Title | Published |
|---|
| 20150216800 | NEUROPROTECTIVE LIPOSOME COMPOSITIONS AND METHODS FOR TREATMENT OF STROKE - Methods for the treatment of stroke, such as stroke of undetermined origin, by administration of xenon (Xe)-loaded liposome compositions are provided. In some aspects, Xe is encapsulated in echogenic liposomes and release of Xe can be enhanced by application of ultrasound stimulation. Compositions for use in treating stroke, such as liposomes loaded with Xe or Xe in combination with H2 or H2S, are also provided. | 2015-08-06 |
| 20150216801 | STABLE OXALIPLATIN-ENCAPSULATING LIPOSOME AQUEOUS DISPERSION AND METHOD FOR STABILIZING SAME - An object of the present invention is to provide an oxaliplatin-encapsulating liposome aqueous dispersion that has excellent long-term storage stability. The present invention provides an aqueous dispersion of liposomes encapsulating oxaliplatin, the oxaliplatin-encapsulating liposome aqueous dispersion containing 2-morpholinoethanesulfonic acid in an external aqueous phase. | 2015-08-06 |
| 20150216802 | LIPOSOME COMPOSITION FOR USE IN PERITONEAL DIALYSIS - The present invention is directed to a liposome composition for use in the peritoneal dialysis of patients suffering from endogenous or exogenous toxicopathies, wherein the pH within the liposomes differs from the pH in the intraperitoneal cavity and wherein the pH within the liposome results in a liposome-encapsulated charged toxin. The invention also relates to a pharmaceutical composition comprising said liposomes. A further aspect of the present invention relates to a method of treating patients suffering from endogenous or exogenous toxicopathies, preferably selected from drug, metabolite, pesticide, insecticide, toxin, and chemical warfare toxicopathies, more preferably hyperammonemia, comprising the step of administering liposomes of the invention in a therapeutically effective amount into the peritoneal space of a patient in need thereof. Next to human, the present invention is particularly suitable to veterinary aspects. | 2015-08-06 |
| 20150216803 | LIPID ASSEMBLIES COMPRISING ANIONIC LYSOLIPIDS AND USE THEREOF - The present invention relates to lipid assemblies, compositions, and liposomal delivery systems comprising single chain anionic lipids, and the use thereof in diagnosis and therapy. It involves the use of anionic lysolipids for modifying the surface charge of a cationic lipid composition consisting at least one type of cationic lipid, optionally in combination with one or more neutral lipids and/or one or more anionic lipids. | 2015-08-06 |
| 20150216804 | PREPARATION CONTAINING 6,7-UNSATURATED-7-CARBAMOYL MORPHINAN DERIVATIVES - The solid preparation which improved the dissolution profile and the stability of the 6,7-unsaturation-7-carbamoyl morphinan derivative is provided. When 6,7-unsaturation-7-carbamoyl morphinan derivative, croscarmellose sodium and ferric oxide were contained, not titanium oxide in the solid preparations and the coating solid preparations, a dissolution rate after 15 minutes of the dissolution test is more than 85%, and stability, particularly, light stability can be improve. | 2015-08-06 |
| 20150216805 | SINGLE STROKE COMPRESSION MOLDING MACHINE AND METHOD OF PRODUCING COMPRESSION MOLDED PRODUCT - The invention provides a single stroke compression molding machine including: a die table having a die bore penetrating vertically; a slidable lower punch located below the die bore and having an upper end to be inserted to the die bore; a slidable upper punch located above the die bore to face the lower punch and having a lower end to be inserted to the die bore; and a dust collector configured to collect dust on an upper surface of the die table in a state where the lower end of the upper punch is located in the die bore. | 2015-08-06 |
| 20150216806 | LAXATIVE COMPOSITIONS AND METHODS FOR TREATING CONSTIPATION AND RELATED GASTROINTESTINAL DISEASES AND CONDITIONS - In alternative embodiments, the invention provides compositions, e.g., formulations or preparations, used for treating, ameliorating or preventing constipation and other disorders with related gastrointestinal symptoms. In alternative embodiments, the invention provides compositions, e.g., formulations or preparations, used for treating, ameliorating or preventing conditions which benefit from increasing or speeding bowel transit, including for example: cyclic vomiting, reflux oesophagitis, autism enteropathy, flatulence, halitosis, Chronic Fatigue Syndrome (CFS), bloating, proctalgia fugax, small intestinal bacterial overgrowth (SIBO) and large intestinal bacterial overgrowth (LIBO), chronic nausea, functional dyspepsia and bloating. In alternative embodiments, the invention provides compositions, e.g., formulations or preparations, used for treating, ameliorating or preventing a constipation, a functional constipation, Irritable Bowel Syndrome (IBS)-constipation, a diverticulosis-associated constipation, a pseudo obstruction, a slow-transit constipation, a stasis with overflow and/or a diabetic gastro-paresis. In alternative embodiments, the invention provides pharmaceuticals and products (articles) of manufacture for delivering these compositions and formulations to an individual, e.g., a human or an animal. | 2015-08-06 |
| 20150216807 | SOLUBILIZED COQ-10 - The present invention is directed to compositions and methods of delivery of CoQ-10 solubilized in monoterpenes. Use of monoterpenes as dissolving agents, greatly effects the ability to incorporate greater amounts of bioactive CoQ-10 in formulations, such as soft gel capsules. | 2015-08-06 |
| 20150216808 | NON-DIGESTIBLE CAPSULES FOR THE DELIVERY OF FLUID ABSORBING MATERIALS - The invention relates to a product, method of use, and/or method of preparing a capsule or capsular like product that comprises hydrophilic fluid-absorbing materials that bind, entrap, and/or absorb large quantities of fluid. The capsules or capsular like product may be capable of diverting the mode of fluid and waste elimination from the renal route to the gastrointestinal route. | 2015-08-06 |
| 20150216809 | CONTROLLED RELEASE HYDROCODONE FORMULATIONS - A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a C | 2015-08-06 |
| 20150216810 | CONTROLLED RELEASE HYDROCODONE FORMULATIONS - A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a C | 2015-08-06 |
| 20150216811 | COMPOSITION AND METHOD FOR AIDING SLEEP - Described is a controlled-release formulation for treating disturbed sleep or insomnia in a subject. The formulation is formulated to release a compound or combination of compounds in sequence at multiple stages. | 2015-08-06 |
| 20150216812 | USE OF DECELLULARIZED EXTRACELLULAR MATRIX FOR ENCAPSULATING CELLS - A microparticle for cell encapsulation is provided, having a core which comprises continuous fibers of decellularized extracellular matrix (ECM). | 2015-08-06 |
| 20150216813 | METHODS FOR MAKING PHARMACEUTICAL SOLID DOSAGE FORMS OF SPRAY-DRIED DISPERSIONS - An exemplary method comprises providing a spray-dried dispersion comprising particles, the particles comprising an active agent and a polymer, the dispersion particles having an average particle diameter of less than 50 μm. An ordered mixture is formed by high-shear mixing the dispersion with a powdered glidant, wherein the average particle diameter of the glidant is less than or equal to one fifth the average particle diameter of the dispersion after high-shear mixing. The dosage forms are formed by at least one of directly compressing the ordered mixture to form a tablet and encapsulating the ordered mixture to form a capsule. | 2015-08-06 |
| 20150216814 | DELIVERY OF SMALL INTERFERING RNA AND MICRO RNA THROUGH MEMBRANE-DISRUPTIVE, RESPONSIVE NANOSCALLE HYDROGELS - Nanoscale, pH-responsive polycationic networks useful for the delivery of anionic biologic therapeutics and associated methods. | 2015-08-06 |
| 20150216815 | DERMAL PAIN RELIEF DELIVERY SYSTEM - An easy to apply dermal delivery system embodying an apparatus and a method for relieving the localized discomfort caused by footwear is provided. The delivery system may include a generally planar base, adhesive layer and delivery apparatus. The base forms a basic recess on one side, whereby the non-recessed portion provides a basic framework along the periphery thereof. The adhesive layer overlaid the recessed-side of a similarly shaped base forms an adhesive recess and an adhesive framework. The delivery apparatus may be sized and shaped to substantially fill the adhesive recess and be substantially flush with a top side of the adhesive framework. The delivery apparatus may include a film, housing and/or impregnated with a plurality of anesthetic components, wherein the film is adapted for dermal delivery of the plurality of anesthetic components, while the adhesive framework removably attaches the delivery system to a user. | 2015-08-06 |
| 20150216816 | COMPOSITIONS, TREATMENT SYSTEMS AND METHODS FOR IMPROVED COOLING OF LIPID-RICH TISSUE - Compositions and formulations for use with devices and systems that enable tissue cooling, such as cryotherapy applications, for alteration and reduction of adipose tissue are described. Aspects of the technology are further directed to methods, compositions and devices that provide protection of non-targeted cells (e.g., non-lipid-rich cells) from freeze damage during dermatological and related aesthetic procedures that require sustained exposure to cold temperatures. Further aspects of the technology include systems for enhancing sustained and/or replenishing release of cryoprotectant to a treatment site prior to and during cooling applications. | 2015-08-06 |
| 20150216817 | METHOD AND COMPOSITION FOR ENHANCING MILK PRODUCTION - The present invention concerns a method of enhancing milk production by a ruminant that includes providing a feed that contains sorbitol and at least one additional feed component, and orally feeding the feed to the ruminant, the ruminant ingesting about 100 grams, or less, of sorbitol per day. | 2015-08-06 |
| 20150216818 | JAVA GINGER EXTRACT AND MANUFACTURING METHOD - The present invention relates to a Java ginger extract which is prepared from Java ginger as a starting material and aimed at a concentrate as an objective (concentrate including solid matter) obtained from a solute. The starting material or the products on any of the steps in which the objective is manufactured from the starting material is heated or exposed to sunlight. In relation to a peak area ratio on high-performance liquid chromatography (HPLC), the peak area ratio (D/M ratio) of a phenyl butenoid dimer represented by the following formula (1) to a monomer represented by the following formula (2) is 0.6 or higher. An intake/dose of the Java ginger extract can be decreased by increasing a content of a phenyl butenoid dimer with an NGF-like action. | 2015-08-06 |
| 20150216819 | AGENTS USEFUL FOR TREATING OBESITY, DIABETES AND RELATED DISORDERS - This invention provides methods of identifying agents useful to prevent, ameliorate or treat one or more symptoms of impaired insulin sensitivity, glucose tolerance, obesity, diabetes, aging, metabolic syndrome, or other metabolic syndrome component diseases, and methods of employing the identified agents to prevent, reduce, delay or inhibit one or more symptoms of impaired insulin sensitivity, glucose tolerance, obesity, diabetes, aging, metabolic syndrome, or other metabolic syndrome component diseases. | 2015-08-06 |
| 20150216820 | QUINONE DERIVATIVES FOR USE IN THE MODULATION OF REDOX STATUS OF INDIVIDUALS - Methods of modulating, adjusting, and maintenance of the glutathione redox status of an individual, or cell, tissues, bodily fluids, or body compartments of the individual, are disclosed, as are compositions suitable for such modulating, adjusting, and maintenance. The modulation or adjustment is achieved by altering the amounts of reduced glutathione versus oxidized glutathione in the individual, or cells, tissues, bodily fluids, or body compartments of the individual. Modulation, adjustment, and maintenance of the redox status of an individual enables treatment, prevention or suppression of diseases or symptoms associated with diseases. These methods are achieved by using quinone derivatives. | 2015-08-06 |
| 20150216821 | ABUSE-PROOFED ORAL DOSAGE FORM - The present invention relates to an abuse-proofed oral dosage form with controlled release of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol for once daily administration, which comprises the active ingredient and/or one or more of the pharmaceutically acceptable salts thereof (A), at least one synthetic or natural polymer (C), delayed-release auxiliary substances, optionally physiologically acceptable auxiliary substances (B) and optionally a wax (D), component (C) or (D) in each case exhibiting a breaking strength of at least 500 N, preferably of at least 1000 N. | 2015-08-06 |
| 20150216822 | NANOPARTICULATE CINACALCET COMPOSITIONS - The invention is directed to compositions comprising stable nanoparticulate cinacalcet or a salt thereof. The composition can exhibit an improved dissolution rate, improved bioavailability, and reduced difference in absorption when administered orally under fed as compared to fasting conditions. The invention also encompasses methods of making and using such compositions. | 2015-08-06 |
| 20150216823 | COMPOSITIONS FOR THE TREATMENT OF MIGRAINE HEADACHES AND METHODS THEREOF - Provided herein formulations of capsaicin for delivery by nasal route and methods of using the formulations for the treatment of migraines and other severe headaches. The formulations described herein contain mucoadhesives to optimize the therapeutic effect of capsaicin by intranasal delivery. | 2015-08-06 |
| 20150216824 | Treatment of Medium-Chain Acyl-CoA Dehydrogenase Deficiency - The present invention provides for methods and compositions for treating medium chain acyl-CoA dehydrogenase deficiency. It is based, at least in part, on the discovery that phenylbutyrate can serve as a substrate for medium chain acyl-CoA dehydrogenase. In non-limiting embodiments, phenylbutyrate and/or another source of phenylacetate is administered as a chaperone treatment to patients suffering from medium chain acyl-CoA dehydrogenase deficiency. | 2015-08-06 |
| 20150216825 | ORGANIC ACIDS AS GROWTH INHIBITORS OF PATHOLOGICAL CALCIFICATION AND USES THEREOF - In an embodiment of the present disclosure, there is provided a composition for inhibiting calcium oxalate crystal growth. In an embodiment of the present disclosure, there is provided a composition for inhibiting calcium phosphate crystal growth. In some embodiments, such a composition comprises at least one citrate derivative of an organic acid and at least one pharmaceutically acceptable carrier. In another embodiment, the present disclosure relates to a method of controlling calcium oxalate crystal growth in a subject in need thereof. Such a method comprises administering to the subject an effective amount of the aforementioned composition. In another embodiment, the present disclosure pertains to a method of treating kidney stone disorder. Such a method comprises administering to a subject in need thereof a therapeutically effective amount of the aforementioned composition. In yet another embodiment, the present disclosure relates to a method of treating calcium oxalate stone disease. In an embodiment, the method comprises administering to a subject in need thereof a therapeutically effective amount of the aforementioned composition. | 2015-08-06 |
| 20150216826 | NANOEMULSION THERAPEUTIC COMPOSITIONS AND METHODS OF USING THE SAME - The present invention relates to therapeutic nanoemulsion compositions and to methods of utilizing the same. In particular, nanoemulsion compositions are described herein that find use in the treatment and/or prevention of infection (e.g., respiratory infection (e.g., associated with cystic fibrosis)), in burn wound management, and in immunogenic compositions (e.g., comprising a | 2015-08-06 |
| 20150216827 | Compositions and Methods for Treating Intestinal Hyperpermeability - The present invention provides methods, compositions, and kits for treating intestinal hyperpermeability in a subject in need thereof, including conditions such as hyperglycemia and underlying diseases such as diabetes, autism, fibromyalgia, inflammatory bowel disease (IBD), graft versus host disease (GVHD), HIV/AIDS, multiple organ dysfunction syndrome, irritable bowel syndrome (IBS), celiac disease, eczema, psoriasis, acute pancreatitis, Parkinson's disease, depression, chronic fatigue syndrome, asthma, multiple sclerosis, arthritis, ankylosing spondylitis, nonalcoholic fatty liver disease, alcoholic cirrhosis, environmental enteropathy, or kwashiorkor. | 2015-08-06 |
| 20150216828 | Production of Omega-3 Long Chain Polyunsaturated Fatty Acids - A recombinant | 2015-08-06 |
| 20150216829 | Compounds and Methods for Modulating Vascular Injury - Methods of modulating healing response to vascular injury and/or vascular scarring in a subject are provided. As such, aspects of the disclosure relate to the use of pro-resolving lipid mediators to modulate inflammation and/or restenosis of a vascular wall. Another aspect of the disclosure relates to the use of pro-resolving lipid mediators to modulate a biological activity of vascular smooth muscle cells (VSMC) or vascular endothelial cells (VEC). Pro-resolving lipid mediators that find use in the subject methods include derivatives of omega-3 polyunsaturated fatty acids and omega-6 polyunsaturated fatty acids, such as resolvins, protectins, lipoxins and maresins and their therapeutically stable analogs. Also provided are vascular devices and compositions for use in the subject methods. Such methods, devices and compositions find use in a variety of applications, including applications related to treatment of vascular injuries and vascular scarring (e.g., restenosis), and applications related to chronic inflammatory diseases of the vascular wall. | 2015-08-06 |
| 20150216830 | 5-AMINOLEVULINIC ACID DERIVATIVES, METHODS FOR THEIR PREPARATION AND USES THEREOF - There are provided conjugates comprising 5-aminolevulinic acid (5-ALA), an aldehyde and a carboxylic acid (e.g., a histone deacetylase inhibitor), compositions comprising same, methods for their preparation and uses thereof for treatment of cancer and anemia, and for inducing erythropoiesis. | 2015-08-06 |
| 20150216831 | Methods of Reducing Apolipoprotein C-III - In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. | 2015-08-06 |
| 20150216832 | METHOD FOR TREATING INFLAMMATION BY ADMINISTERING A COMPOUND WHICH BINDS LDL-RECEPTOR-RELATED PROTEIN (LRP) LIGAND BINDING DOMAIN - The present invention relates to the field of therapeutic methods, compositions and uses thereof, that affect, directly or indirectly, the behavior of LRP receptors. These compositions and methods result in the treatment of inflammatory, immunological and metabolic conditions. More particularly, the methods and compositions of the invention are directed to the identification of small molecules, drugs and/or pharmacological agents that affect the Wnt pathway by affecting normal complex formation among various signaling receptors, the LRP5 and LRP6 receptor, and related ligands. | 2015-08-06 |
| 20150216833 | Therapeutic for Treating Inflammatory Lung Disorders - A calcium/cation-sensing receptor (CaSR) antagonist to treat an inflammatory lung disorder is described. Methods of treatment including the antagonist, combination therapeutics including the antagonist and at least one other agent, and nebulisers or inhalers including the antagonist are also described. | 2015-08-06 |
| 20150216834 | PHARMACEUTICAL/COSMETIC, E.G., ANTI-ACNE COMPOSITIONS COMPRISING AT LEAST ONE NAPHTOIC ACID COMPOUND, BENZOYL PEROXIDE AND AT LEAST ONE FILM-FORMING AGENT - Stable pharmaceutical/cosmetic compositions for topical application, notably for the treatment of acne vulgaris include, formulated into a physiologically acceptable medium, at least one naphthoic acid compound, benzoyl peroxide and at least one film-forming agent, the at least one naphthoic acid compound and the benzoyl peroxide advantageously being in a dispersed form therein. | 2015-08-06 |
| 20150216835 | METHODS OF TREATING AN OVERWEIGHT OR OBESE SUBJECT - The invention herein generally relates to pharmaceutical formulations and methods of treating an overweight or obese subject, and overweight- or obesity-related conditions. | 2015-08-06 |
| 20150216836 | ANTICANCER FORMULATION - This invention relates to a pharmaceutical formulation containing z-butylidenephthalide and a polymer, e.g., a polyanhydride. Also disclosed is use of this formulation to treat tumor. | 2015-08-06 |
| 20150216837 | TREATMENT OF CIRCADIAN RHYTHM DISORDERS - Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm. | 2015-08-06 |
| 20150216838 | Neuraminidase Inhibitor Compounds, Compositions and Methods for the Use Thereof in Anti-Viral Treatments - Compounds having a structure of Formula I and compositions comprising these compounds are provided. Uses of such compounds and compositions are provided for treatment or prophylaxis of viral infection. In particular, compounds and compositions may be for use in the treatment or prophylaxis of viral influenza. | 2015-08-06 |
| 20150216839 | COMPOSITIONS OF BIOACTIVE POLYELECTROLYTES FROM HUMIFIED ORGANIC MATERIALS AND USES THEREOF - Topical compositions containing an isolated BP fraction and an active agent, and uses of the composition to improve a skin condition are described. | 2015-08-06 |
| 20150216840 | Method of Treating Acne - The use, as a dermatological or cosmetic medicament, of compounds capable of transiently interacting with the AhR receptor (aryl hydrocarbon receptor) as agents for modulating skin functions such as sebaceous function, skin healing, skin atrophy termed “dermatoporosis”, estrogen deprivation and defense against infection, without inducing other toxic effects of the TCDD type. | 2015-08-06 |
| 20150216841 | Prodrug of Green Tea Epigallocatechin-3-Gallate (Pro-EGCG) for Use in the Treatment of Endometriosis - Method of treating endometriosis and related indications, comprising the administration of Pro-EGCG, a synthetic and derivative product of epigallocatechin-3-gallate [(−)-EGCG]. Use of Pro-EGCG in the manufacture of a medicament for treating endometriosis and related indications. Pro-EGCG for use in the treatment of endometriosis and related indications. | 2015-08-06 |
| 20150216842 | METHODS OF TREATING SKIN CONDITIONS USING CYCLOLIGNAN COMPOUNDS - The present invention includes compositions and methods for the treatment of skin conditions by administration of a cyclolignan such as picropodophyllin and/or a derivative, metabolite, analog, prodrug, pharmaceutically acceptable salt, or hydrate thereof. | 2015-08-06 |
| 20150216843 | INHIBITION OF CXCR4 SIGNALING IN CANCER IMMUNOTHERAPY - The inventions describes a method for increasing effector T cell accumulation in cancer cell-containing sites of a tumor, comprising administering to a subject in need thereof a pharmaceutically effective amount of an inhibitor of CXCR4 signaling. | 2015-08-06 |
| 20150216844 | SUBSTITUTED CC-1065 ANALOGS AND THEIR CONJUGATES - This invention relates to novel agents that are analogs of the DNA-alkylating agent CC-1065 and to their conjugates. Furthermore this invention concerns intermediates for the preparation of said agents and their conjugates. The conjugates are designed to release their (multiple) payload after one or more activation steps and/or at a rate and time span controlled by the conjugate in order to selectively deliver and/or controllably release one or more of said DNA alkylating agents. The agents, conjugates, and intermediates can be used to treat an illness that is characterized by undesired (cell) proliferation. As an example, the agents and the conjugates of this invention may be used to treat a tumor. | 2015-08-06 |
| 20150216845 | IPA AS A THERAPEUTIC AGENT, AS A PROTECTIVE AGENT, AND AS A BIOMARKER OF DISEASE RISK - Indole-3-propionic acid as a marker and for treatment for Huntington Disease. | 2015-08-06 |
| 20150216846 | N-Carbamoylmethyl-4-(R)-Phenyl-2-Pyrrolidinone, Method of its Preparation and Pharmaceutical Use - The invention relates to the R-enantiomer of N-carbamoylmethyl-4-phenyl-2-pyrrolidinone (R-Carphedon) of pharmacological value. The method of its preparation includes the N-alkylation of 4(R)-phenyl-2-pyrrolidinone with ethyl bromoacetate in the presence of a strong base and the treatment of intermediate N-ethoxycarbonylmethyl-4(R)-phenyl-2-pyrrolidinone with ammonia. | 2015-08-06 |
| 20150216847 | CYCLOPROPANECARBOXYLIC ACID DERIVATIVE - A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein R | 2015-08-06 |
| 20150216848 | COMPOUNDS THAT INHIBIT TAU PHOSPHORYLATION - The present invention provides methods and compositions for enhancing working memory impaired in a tau pathological condition associated with AD or Down's syndrome. | 2015-08-06 |
| 20150216849 | DONEPEZIL COMPOSITIONS AND METHODS OF TREATING ALZHEIMERS DISEASE - Oral dosage forms comprising donepezil or a pharmaceutically acceptable salt thereof (e.g., donepezil hydrochloride) alone or in combination with a second active ingredient (e.g., memantine hydrochloride or a pharmaceutically acceptable salt thereof) for the treatment of Alzheimer's disease are provided. The oral dosage forms comprise donepezil granules that may be sprinkled on food and can significantly improve compliance in patients with swallowing difficulty. | 2015-08-06 |
| 20150216850 | COMBINATION OF RASAGILINE AND PRIDOPIDINE FOR TREATING NEURODEGENERATIVE DISORDERS, IN PARTICULAR HUNTINGTON'S DISEASE - This invention provides a method of treating a patient afflicted with a neurodegenerative disorder, e.g., Huntington's disease, comprising administering to the patient rasagiline as an add-on therapy to or in combination with pridopidine. This invention also provides a package and a pharmaceutical composition comprising rasagiline and pridopidine for treating a patient afflicted with a neurodegenerative disorder. This invention also provides rasagiline for use as an add-on therapy or in combination with pridopidine in treating a patient afflicted with a neurodegenerative disorder. This invention further provides use of rasagiline and pridopidine in the preparation of a combination for treating a patient afflicted with a neurodegenerative disorder. | 2015-08-06 |
| 20150216851 | Polymorphs of Cocrystals of p-Coumaric Acid:Nicotinamide - Polymorphs, Forms II and III, of cocrystals of p-coumaric acid and nicotinamide in a 1:1 molar ratio. Pharmaceutical compositions containing Forms II or III, processes for making such forms, and methods of treatment with such Forms. | 2015-08-06 |
| 20150216853 | METHOD OF SCREENING ANTI-PLASMODIAL ACTIVITY OF ACRIFLAVIN AND ACRIFLAVIN AS AN ANTI-MALARIAL AGENT - The present invention provides a method of screening anti-plasmodial activity of Acriflavin, comprising assessing growth inhibition of | 2015-08-06 |
| 20150216854 | Use Of Flap Inhibitors To Reduce Neuroinflammation Mediated Injury In The Central Nervous System - The present invention provides methods of attenuating or preventing brain injury mediated damage in the central nervous system by attenuating or preventing leukotriene-mediated events following a brain injury or long-term neuroinflammation after brain injury, in Alzheimer's disease, multiple sclerosis, stroke, and post-traumatic stress disorder. The methods comprise administering at least one 5-lipoxygenase activating protein (FLAP) inhibitor either before or after the brain injury. The method finds use in the treatment of traumatic brain injury (TBI), stroke, multiple sclerosis, Alzheimer's disease, post-traumatic stress disorder and other brain injuries associated with production of leukotrienes in the central nervous system. Preferably the FLAP inhibitor is administered intranasally and preferably for certain high risk individuals prophylactically prior to any potential brain injury event. | 2015-08-06 |
| 20150216855 | Modulators of Hepatic Lipoprotein Metabolism - The present invention relates to compounds that are useful for modulating hepatic cholesterol metabolism in an animal. The invention includes methods of making and using the compounds of the invention. The invention further provides methods of treating, preventing and/or alleviating a cholesterol related disorder, a cardiovascular disease and/or liver disease in an animal, such as a human, comprising administering compounds of the invention, or pharmaceutically acceptable salts or solvates thereof, to the animal. | 2015-08-06 |
| 20150216856 | STABLE PHARMACEUTICAL COMPOSITION COMPRISING SOLIFENACIN, AND METHOD FOR PREPARING THE SAME - The present invention relates to a solifenacin preparation containing solifenacin or a pharmaceutically acceptable salt thereof, an antioxidant, and a binder, which is manufactured via direct compression. Compared to the preparations manufactured via conventional wet granulation process, the preparation of the present invention can be manufactured by a simplified process such as direct compression, and has improved content uniformity, mixing degree, etc., even when the preparation is manufactured by high speed tableting. | 2015-08-06 |
| 20150216857 | COMPOSITIONS AND METHODS FOR TREATMENT - The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists. | 2015-08-06 |
| 20150216859 | SUBLINGUAL APOMORPHINE - The invention features sublingual formulations of apomorphine and apomorphine prodrugs, and methods of treating Parkinson's disease, sexual dysfunction, and depressive disorders therewith. | 2015-08-06 |
| 20150216860 | THERAPEUTIC AGENT FOR SYSTEMIC BONE DISEASE AND USE THEREOF - The object is to provide a novel therapeutic strategy achieving high therapeutic effect on a skeletal dysplasia caused by excessive activation of FGFR3, particularly achondroplasia and hypochondroplasia. Provided is a therapeutic agent for a skeletal dysplasia, including meclizine or its pharmaceutically acceptable salt as an active ingredient. | 2015-08-06 |
| 20150216861 | CYCLOPROPYL AMIDE DERIVATIVES - Disclosed herein is at least one cyclopropyl amide derivative, at least one pharmaceutical composition comprising at least one cyclopropyl amide derivative disclosed herein, and at least one method of using at least one cyclopropyl amide derivative disclosed herein for treating at least one histamine H3 receptor associated condition therewith. | 2015-08-06 |
| 20150216862 | 2,2'-BIPHENAZINE COMPOUNDS AND METHODS USEFUL FOR TREATING DISEASES - The invention relates to a chemotherapeutic cancer treatment in which compounds (BH3Is) are administered to a mammal to treat B-cell Lymphoma or other hematopoietic cancers, including diseases associated with MCL-1. The invention also provides a method for treating types of hematopoietic cancers, such as B-cell lymphoma, using a combination of one or more disclosed compounds in combination with other therapes, for example, 26S proteasome inhibitors, such as, for example, Bortezomib. The invention also relates to autoimmune treatment with pharmaceutical compositions comprising one or more disclosed compounds. The invention also relates to methods for identifying compounds, for example, compounds of the BH3 mimic class, that have unique in vitro properties that predict in vivo efficacy against B-cell lymphoma tumors and other cancers as well as autoimmune disease. | 2015-08-06 |
| 20150216863 | SUBSTITUTED BICYCLIC ALKOXY PYRAZOLE ANALOGS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS - In one aspect, the invention relates to substituted bicyclic alkoxy pyrazole analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 2015-08-06 |
| 20150216864 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS - Polycyclic heteroaryl substituted triazoles and pharmaceutical compositions containing the compounds are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the compounds in treating diseases or conditions associated with Axl activity are also disclosed. | 2015-08-06 |
| 20150216865 | METHODS OF TREATING A BRUTON'S TYROSINE KINASE DISEASE OR DISORDER - The present invention provides methods of treating, stabilizing or lessening the severity or progression of a disease or disorder associated with BTK. | 2015-08-06 |
| 20150216866 | SUBSTITUTED BENZYLAMINO QUINOLINES AS CHOLESTEROL ESTER-TRANSFER PROTEIN INHIBITORS - The present invention provides a method for treating or preventing a condition or disease in a human or an animal subject wherein the condition or disease is associated with lipoprotein metabolism, the method comprising administering to the subject a composition comprising benzylamine compounds. | 2015-08-06 |
| 20150216867 | COMPOUNDS FOR USE IN GASTRIC COMPLICATION - The present invention relates to the use of low molecular weight (lmw) compounds, especially lmw compounds with GPR4-affinity, in the treatment of diseases and disorders which includes gastroesophageal reflux disease (GERD), and/or non-erosive reflux disease (NERD) and the like. | 2015-08-06 |
| 20150216868 | Method of Adjuvant Cancer Treatment - The present invention provides a method of providing adjuvant treatment to a human patient which comprises administering to such a patient therapeutically effective doses of dabrafenib and trametinib for a time period sufficient to increase relapse-free survival (RFS). | 2015-08-06 |
| 20150216869 | Drug Combinations and Uses in Treating a Coughing Condition - The present specification discloses compositions comprising a plurality of therapeutic compound having antitussive activity and methods and uses for treating a coughing condition with such compositions. | 2015-08-06 |
| 20150216870 | Combination of PI3K Inhibitor and C-Met Inhibitor - The present invention relates to a pharmaceutical combination which comprises (a) a phosphatidylinositol 3-kinase inhibitor or pharmaceutically acceptable salt thereof, and (b) at least one c-Met receptor tyrosine kinase inhibitor or pharmaceutically acceptable salt thereof, for simultaneous, separate or sequential administration for the treatment of a proliferative disease, particularly a c-Met dependent proliferative disease; a pharmaceutical composition comprising such combination; a method of treating a subject having a proliferative disease comprising administration of said combination to a subject in need thereof; use of such combination for the treatment of proliferative disease; and a commercial package comprising such combination. | 2015-08-06 |
| 20150216871 | Use of a Humic Acid Preparation for Treating Warm-Blooded Animals - The invention relates to the use of a humic acid preparation RB4 or lignocellulose carbon isolate for treating diseases in warm-blooded animals cause by glyphosate herbicide, whereby the glyphosate herbicide is bound to the humic acid preparation and reduced the growth-inhibiting effect of glyphosate herbicide on physiological germs. The invention also related to the use of humic acid preparation RB4 or lignocellulose carbon isolate for external skin application so that it leads to the improvement or maintenance of skin health. | 2015-08-06 |
| 20150216872 | METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES WITH CERAMIDE DERIVATIVES - A method of treating polycystic kidney disease in a subject comprises administering to the subject an effective amount of a compound represented by Structural Formula (1): | 2015-08-06 |
| 20150216873 | METHODS OF TREATING PATIENTS CO-INFECTED WITH HIV AND TUBERCULOSIS - The disclosure describes methods for treatment of patients co-infected with HIV and tuberculosis, wherein the patient receives effective amounts of elvitegravir, an antimycobacterial agent and a CYP inhibitor. | 2015-08-06 |
| 20150216874 | ANTIBIOTIC COMPOSITIONS AND METHODS - Disclosed is a novel family of antibiotic that provides bacteria specific targeting, activation and the ability to prevent bacteria mutations that result in bacteria resistance. The compositions and methods of the invention provide for an antibiotic that is effective against Methicillin-resistant | 2015-08-06 |
| 20150216875 | MODULATING THE PRODUCTION OF NEURONS AND/OR OLIGODENDROCYTES FROM WHITE MATTER PROGENITOR CELLS - The present invention relates to a method of modulating production of neurons and/or oligodendrocytes from neural progenitor cells of human white matter and to a method of treating a subject for a condition modulated by underproduction of oligodendrocytes from human white matter. Both of these methods involve administering an agonist or antagonist of one or more molecules set forth in Tables 1 and/or 2 to the neural progenitor cells. Also disclosed is a method of using an inhibitor of sterol synthesis to differentiate oligodendrocyte progenitor cells to oligodendrocytes. | 2015-08-06 |
| 20150216876 | METHOD FOR TREATING INFLAMMATORY CONDITIONS - A method for treating an autoimmune disease in a subject includes administering to the subject a therapeutically effective amount of an agent comprising an imidazole, an estrogen receptor agonist, or pharmaceutically acceptable salts thereof. | 2015-08-06 |
| 20150216877 | COMPOSITIONS AND TREATMENT FOR EYE DISEASES AND DISORDERS - The invention relates to compositions and methods for treating eye diseases and disorders. More specifically, the invention provides compositions comprising progesterone and methods of treating ocular surface diseases and disorders comprising applying such compositions topically. | 2015-08-06 |
| 20150216878 | 17 Alpha, 21-Dihydroxypregnene Esters as Antiandrogenic Agents - 17α,21 -Dihydroxypregna-4,9(11)-diene-3,20-dione and 17α,21-dihydroxypregna-4-ene-3,20-dione 17 and/or 21 esters having remarkable antiandrogenic activity and processes for the preparation thereof. | 2015-08-06 |
| 20150216879 | Methods and Compositions for the Treatment of Fluid Accumulation in and/or Under the Retina - The present invention provides methods and compositions for the treatment of fluid accumulation in and/or under the retina. | 2015-08-06 |
| 20150216880 | INDUCING LACTATION IN NURSING FEMALES - A topical cream applied to a nipple of a lactating female induces lactation. The cream comprises a base cream having from about 0.5% to about 10%, by volume, of a steroid, based upon the total volume of the cream. The preferred steroid is stanozolol. Preferably, the cream comprises at least about 1% to about 10%, by volume, of stanozolol, based on the total volume of the cream. | 2015-08-06 |
| 20150216881 | Method for Treating Secondary Hyperparathyroidism in CKD - A stable, controlled release formulation for oral dosing of vitamin D compounds is disclosed. The formulation is prepared by incorporating one or more vitamin D compounds into a solid or semi-solid mixture of waxy materials. Oral dosage forms can be prepared by melt-blending the components described herein and filling gelatin capsules with the formulation. | 2015-08-06 |
| 20150216882 | High-Purity Phospholipids - Novel synthetic routes, which are highly applicable for industrial preparation of therapeutically beneficial oxidized phospholipids, are disclosed. Particularly, novel methods for efficiently preparing compounds having a glycerolic backbone and one or more oxidized moieties attached to the glycerolic backbone, which are devoid of column chromatography are disclosed. Further disclosed are novel methods of introducing phosphorus-containing moieties such as phosphate moieties to compounds having glycerolic backbone and intermediates formed thereby. Further disclosed is substantially pure 1-hexadecyl-2-(4′-carboxy)butyl-sn-glycero-3-phosphocholine (CI-201). | 2015-08-06 |
| 20150216883 | DIETARY SUPPLEMENT CONTAINING PHOSPHOLIPID-DHA DERIVED FROM EGGS - Described herein are manufactured dietary supplements that contain a phospholipid extract and the extract contains two forms of phospholipid-docosahexanoic acid. One form of phospholipid-docosahexanoic acid is phosphatidylcholine-docosahexanoic acid, and another form of phospholipid-docosahexanoic acid is phosphatidylethanolamine-docosahexanoic acid. | 2015-08-06 |
| 20150216884 | Compositions for Oral Administration of Zoledronic Acid or Related Compounds for Treating Low Back Pain - Oral dosage forms of bisphosphonate compounds, such as zoledronic acid, can be used to treat or alleviate pain or related conditions. The oral bioavailability of zoledronic acid can be enhanced by administering the zoledronic acid in the disodium salt form | 2015-08-06 |
| 20150216885 | BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS - Methods of treating anti-inflammatory conditions through the use of boron-containing small molecules are disclosed. | 2015-08-06 |
| 20150216886 | METHODS FOR TREATING CANCERS USING ORAL FORMULATIONS OF CYTIDINE ANALOGS - Provided herein are methods for treating subjects having a cancer, such as a relapsed or refractory solid tumor, wherein the method comprises administering to the subject a cytidine analog. In certain of the methods, the cytidine analog is administered alone or in combination with one or more anti-cancer agents. Also provided are methods for using a cytidine analog, to treat diseases and disorders including disorders related to abnormal cell proliferation, hematologic disorders, and immune disorders, among others. In certain of the methods, the cytidine analog is formulated in an oral dosage form and administered orally. | 2015-08-06 |
| 20150216887 | Compositions for Oral Administration to Animals, Production Methods thereof and Uses of Same - The invention relates to a method for the production of a time-stable, solid appetising composition and to the use thereof, said composition comprising at least one active substance which is introduced in the final production step, by adding same to the already formed mixture of other components at ambient temperature, without the use of water or heat. The composition is intended for use as a drug, a nutraceutical or a food supplement for oral administration to mammals, except humans, in particular for pets such as dogs, cats or horses. The stable solid composition is obtained by compressing the mixture using a press for compressing formulations having a high fat content. | 2015-08-06 |
| 20150216888 | ANTIPARASITIC POLYANHYDRIDE NANOPARTICLES - Filarial parasites | 2015-08-06 |
| 20150216890 | METHOD OF TREATING LEUKEMIA - The present invention relates to methods of treating disorders in which DOT1L-mediated protein methylation plays a part, such as cancer, by administering DOT1L inhibitor compounds and pharmaceutical compositions to subjects in need thereof. | 2015-08-06 |
| 20150216891 | NUCLEIC ACIDS TARGETING TCTP FOR USE IN THE TREATMENT OF CHEMO-OR HORMONE- RESISTANT CANCERS - The present invention concerns a TCTP antagonist, in particular a nucleic acid targeting an m RNA encoding Translationally-Controlled Tumor Protein (TCTP), wherein said nucleic acid is capable of reducing the amount of TCTP in cells, for use in the treatment or prevention of hormone-independent cancer or chemo-resistant cancer, such as an androgen-independent prostate cancer. | 2015-08-06 |
| 20150216892 | CELL-SPECIFIC DELIVERY OF MIRNA MODULATORS FOR THE TREATMENT OF OBESITY AND RELATED DISORDERS - Compositions comprising microRNAs (miRNAs) and targeting agents are disclosed, as well as methods for delivering a therapeutic composition comprising the same, and the use of these compositions to treat obesity or cardiometabolic disorders. In some aspects, the compositions comprise a miRNA agent and a targeting agent. In some embodiments, the targeting agent may be an aptamer, an exosome, or both an aptamer and an exosome. | 2015-08-06 |
| 20150216893 | METHODS AND COMPOSITIONS FOR INHIBITING A MULTI-CANCER MESENCHYMAL TRANSITION MECHANISM - The present invention relates to the discovery that the modulation of particular microRNAs can be employed to inhibit a mesenchymal transition that, in certain instances, correlates with resistance to therapy and recurrence as the corresponding cells acquire properties of stem cells as they start undergoing this transition, as well as with invasiveness, e.g., invasion of certain cells of primary tumors into adjacent connective tissue during the initial phase of metastasis. Accordingly, the identification inhibitors of this mechanism, such as inhibitors of certain microRNAs, disclosed herein, can be used for inhibiting the mesenchymal transition to reduce the invasive nature of certain cells of primary cancerous tumors and, in certain instances, to prevent the recurrence of cancer by inhibiting the induction of stem cell-like features in certain cancer cells. | 2015-08-06 |
| 20150216894 | Chitosan Materials from Carbonic Acid Solution - The present invention comprises chitosan materials and methods of using carbonic acid for aqueous solubilization of neutralized or pre-treated chitosan gels and provides, among other things, substantially acid salt free composition native final forms without requiring subsequent acid salt elution. The invention includes chitosan-based solid and semi-solid material forms, optionally reinforced with chitosan fibers, such as powders, fibers, films, matrices, sponges, implants, scaffolds, fillers, and hydrogels. Native final forms are produced from chitosan powder solubilized in an aqueous acidic solution, processed to form a high pH hydrated chitosan gel precipitate material that is then neutralized by water washing and re-solubilized substantially to chitosan solution using carbonic acid. Chitosan materials can be mixed in solution with one or more of other hydrophilic polymers to create compositional heterogeneity and pharmaceutical agents to achieve controlled release of the agent(s) from the final forms at the site of application. | 2015-08-06 |
| 20150216895 | CYCLODEXTRIN FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES - The invention provides for methods of treating lysosomal storage disorders and/or reduction of non-cholesterol lipids, using cyclodextrin compounds, including in combination with other therapeutics, including vitamin E. | 2015-08-06 |
| 20150216896 | MICELLE SEQUESTERING POLYMERS - A polymer composition for sequestering lipid-bile acid micelles in the gastrointestinal (GI) tract is provided. The polymer composition comprises a copolymer of a pH-sensitive monomer and one or more of positively-charged monomers. The polymer composition is able to bind micelles under various physiological conditions in the GI tract and possesses the ability to flocculate the bound micelle upon exposure to a particular pH. The flocculation of the polymer:micelle complex prevents absorption of the micelle thereby causing the polymer:micelle complex to be eliminated with the fecal matter. Thus, the polymer composition described herein may be effective in reducing cholesterol, bile acid, and/or triglyceride levels and promote weight loss. | 2015-08-06 |
| 20150216897 | USE OF XENON AS NEUROPROTECTANT IN A NEONATAL SUBJECT - The present invention relates to the use of xenon in the preparation of a medicament for preventing and/or alleviating one or more anesthetic-induced neurological deficits in a neonatal subject. | 2015-08-06 |
| 20150216898 | COMPOSITION FOR TREATING PSORIASIS - A dermal composition for treating or soothing psoriasis lesions, wherein the composition comprises a tar extract, a corticosteroid, an antipruritic, an antibiotic, urea, an absorption base, water, lanolin, and propylene glycol. | 2015-08-06 |
| 20150216899 | EXOSOME-BASED THERAPEUTICS AGAINST NEURODEGENERATIVE DISORDERS - Methods and compositions involving exosomes or lipid nanovesicles are provided. For example, certain aspects relate to compositions comprising exosomes obtained from cells that have been induced to undergo oxidative stress or stimulated. Furthermore, some aspects of the invention provide methods of treating a subject at risk or having a demyelinating disorder using the compositions. | 2015-08-06 |
| 20150216900 | Enhancement of Allogeneic Hematopoietic Stem Cell Transplantation - Methods and compositions are provided to augment the conversion of mixed hematopoietic cell chimerism to complete donor cell chimerism following allogeneic hematopoietic cell transplantation (HCT), where such transplantation may be utilized for treatment of cancer such as leukemia and lymphoma or for other conditions requiring reconstitution of the hematopoietic system, e.g. treatment of anemias, thalassemias, autoimmune conditions, and the like. The present invention improves on conventional DLI by utilizing a composition of substantially purified donor memory CD8 | 2015-08-06 |
| 20150216901 | ELIMINATION OF IMMUNE RESPONSES TO VIRAL VECTORS - The present invention relates to the use of immunogenic peptides comprising a T-cell epitope derived from a viral vector antigen and a redox motif such as C-(X)2-[CST] or [CST]-(X)2-C in the prevention and/or suppression of immune responses to viral vectors and in the manufacture of medicaments therefore. | 2015-08-06 |
| 20150216902 | PHARMACEUTICAL COMPOSITION OF MILK FAT GLOBULES (MFGs) ZINC FREE - A pharmaceutical composition comprising at least 20 wt % of milk fat globules (MGFs) and at least one C | 2015-08-06 |
